First Mature Estimation of Median OS for Selpercatinib in Patients with RET Fusion-Positive NSCLC By Ogkologos - March 12, 2025 650 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from final efficacy and safety analyses from the LIBRETTO-001 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Niraparib / Abiraterone Acetate Lisocabtagene Maraleucel Shows Deep, Durable Responses in Patients with Relapsed or Refractory MZL After at Least Two Previous Lines of Systemic Therapy FDA Updates Safety Labelling for Capecitabine and 5-FU on Risks Associated with DPD Deficiency MOST POPULAR Zooming in: Fine-tuning the picture to diagnose oesophageal cancer earlier August 10, 2021 Longest Follow-Up for ICI Plus TKI Favours Treatment with Avelumab Plus... February 11, 2025 Apple Season is Here! October 1, 2021 3rd Grader Writes Note for Teacher Battling Breast Cancer to Read... May 24, 2019 Load more HOT NEWS Woman Who Died For 27 Minutes Shares Haunting Message When Revived Changing the landscape of children’s cancer treatment Grandma Who Sent Accidental Text To Stranger Spends 6th Thanksgiving With... Pivotal Role of the Institutional Molecular Tumour Board in Evaluating the...
